<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918797</url>
  </required_header>
  <id_info>
    <org_study_id>BBIL/BBV152/2021</org_study_id>
    <nct_id>NCT04918797</nct_id>
  </id_info>
  <brief_title>COVAXIN in a Pediatric Cohort</brief_title>
  <acronym>COVAXIN-Peds</acronym>
  <official_title>A Phase II/III, Open Label, Multicenter Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®) in Healthy Volunteers Ages ≤18 to ≥ 2 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bharat Biotech International Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bharat Biotech International Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the safety, reactogenicity and immunogenicity of three&#xD;
      groups ages ≤18 - &gt;12, ≤12 -&gt;6, ≤ 6 - &gt;2 years of healthy volunteers who receive two doses of&#xD;
      the whole virion inactivated SARS-CoV-2 virus vaccine (COVAXIN®) 28 days apart.&#xD;
&#xD;
      Data will be un-blinded to the third party bio-statistician and an interim analysis will be&#xD;
      performed on day 56 for Immunogenicity, Safety and submitted to CDSCO.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: A Phase II/III, Open Label, Multicenter Study to Evaluate the Safety,&#xD;
      Reactogenicity and Immunogenicity, of the Whole-Virion Inactivated SARS-CoV-2 Vaccine&#xD;
      (COVAXIN®) in Healthy Volunteers ages ≤18 to ≥2 Years.&#xD;
&#xD;
      A total sample size of 525 healthy volunteers.&#xD;
&#xD;
      The study is designed to evaluate the safety, reactogenicity and immunogenicity of three&#xD;
      groups ages ≤18 - &gt;12, ≤12 -&gt;6, ≤ 6 - &gt;2 years of healthy volunteers who receive two doses of&#xD;
      the whole virion inactivated SARS-CoV-2 virus vaccine (COVAXIN®) 28 days apart.&#xD;
&#xD;
      Group1: A total of 175 healthy volunteers ages ≤18-&gt;12, years will be enrolled in this group&#xD;
      and will receive two doses of BBV152 vaccine through intramuscular route on Day 0 and Day&#xD;
      28+2.&#xD;
&#xD;
      Group 2: A total of 175 healthy volunteers ages ≤12-&gt;6, years will be enrolled in this group&#xD;
      and will receive two doses of BBV152 vaccine through intramuscular route on Day 0 and Day&#xD;
      28+2.&#xD;
&#xD;
      Group 3: A total of 175 healthy volunteers ages ≤6-&gt; 2 years will be enrolled in this group&#xD;
      and will receive two doses of BBV152 vaccine through intramuscular route on Day 0 and Day&#xD;
      28+2.&#xD;
&#xD;
      Data will be un-blinded to the third party bio-statistician and an interim analysis will be&#xD;
      performed on day 56 for Immunogenicity, Safety and submitted to CDSCO.&#xD;
&#xD;
      Immunogenicity analysis: A total of 5 ml of blood is collected at days 0, 28+2, 56±7, 118±7&#xD;
      and 208±7. SARS-CoV-2 test will be conducted at the time of screening using RT-PCR and ELISA&#xD;
      method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">January 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reactogenicity</measure>
    <time_frame>Within 7 days after each dose of vaccination</time_frame>
    <description>Occurrence of Solicited Adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenecity</measure>
    <time_frame>6 months</time_frame>
    <description>GMTs of SARS-CoV-2 virus neutralizing antibodies by MNT/PRNT assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>6 months</time_frame>
    <description>The GMT of binding antibodies (bAb's) IgG against spike protein (S1) and Nucleocapsid (N) protein in all three groups.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Unsolicited Adverse Events</measure>
    <time_frame>Within 28 days after each dose of vaccination</time_frame>
    <description>Occurrence of Unsolicited Adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events of Special Interest</measure>
    <time_frame>Through study completion ,an average of 9 months</time_frame>
    <description>Occurrence of Adverse Events of Special Interest</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">525</enrollment>
  <condition>SARS-CoV2 Infection</condition>
  <arm_group>
    <arm_group_label>Study vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SARS-COV2 vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVAXIN</intervention_name>
    <description>Whole-Virion Inactivated SARS-CoV-2 Vaccine (COVAXIN®)</description>
    <arm_group_label>Study vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to provide written informed consent (by the parents or legally&#xD;
             acceptable/authorized representative (LAR) and assent by the children (verbal/oral&#xD;
             assent for the children of age between 7-12 years, and written assent for the children&#xD;
             of age between &gt;12 to 18 years), and Audio video consent for all participants.&#xD;
&#xD;
          2. Participants of either gender of age between ≥2 to ≤18years (Participant should be ≤18&#xD;
             years at the time of Screening of the study).&#xD;
&#xD;
          3. Good general health as determined by the discretion of investigator.&#xD;
&#xD;
          4. Expressed interest and availability to fulfill the study requirements.&#xD;
&#xD;
          5. Agrees not to participate in another clinical trial at any time during the study&#xD;
             period.&#xD;
&#xD;
          6. Agrees to remain in the study area for the entire duration of the study.&#xD;
&#xD;
          7. Willing to allow storage and future use of biological samples for future research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of any other COVID-19 investigational vaccination.&#xD;
&#xD;
          2. Confirmed SARS-CoV-2 at the time of screening using RT-PCR and ELISA method.&#xD;
&#xD;
          3. Temperature &gt;38.0°C (100.4°F) or symptoms of an acute self-limited illness such as an&#xD;
             upper respiratory infection or gastroenteritis within three days prior to each dose of&#xD;
             vaccine.&#xD;
&#xD;
          4. Receipt of an experimental agent (vaccine, drug, device, etc.) within 60 days before&#xD;
             enrollment or expects to receive an investigational agent during the study period.&#xD;
&#xD;
          5. Receipt of any licensed vaccine within four weeks before enrollment in this study.&#xD;
&#xD;
          6. Known sensitivity to any ingredient of the study vaccines, or a more severe allergic&#xD;
             reaction and history of allergies in the past.&#xD;
&#xD;
          7. Receipt of immunoglobulin or other blood products within the three months prior to&#xD;
             vaccination in this study.&#xD;
&#xD;
          8. Immunosuppression as a result of an underlying illness or treatment with&#xD;
             immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation&#xD;
             therapy within the preceding 36 months.&#xD;
&#xD;
          9. Long-term use (&gt;2 weeks) of oral or parenteral steroids (glucocorticoids) or high-dose&#xD;
             inhaled steroids (&gt;800 mcg/day of beclomethasone dipropionate or equivalent) within&#xD;
             the preceding six months (nasal and topical steroids are allowed).&#xD;
&#xD;
         10. Any history of hereditary angioedema or idiopathic angioedema.&#xD;
&#xD;
         11. Any history of anaphylaxis in relation to vaccination.&#xD;
&#xD;
         12. History of congenital diseases.&#xD;
&#xD;
         13. Any history of albumin-intolerance.&#xD;
&#xD;
         14. History of any cancer.&#xD;
&#xD;
         15. History of psychiatric severe conditions likely to affect participation in the study.&#xD;
&#xD;
         16. A bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder, or&#xD;
             prior history of significant bleeding or bruising following IM injections or&#xD;
             venepuncture.&#xD;
&#xD;
         17. Any other serious chronic illness requiring hospital specialist supervision.&#xD;
&#xD;
         18. Respiratory diseases like severe acute respiratory syndrome (SARS), including mild&#xD;
             asthma.&#xD;
&#xD;
         19. Chronic cardiovascular disease, gastrointestinal disease, liver disease, renal&#xD;
             disease, endocrine disorder, and neurological illness&#xD;
&#xD;
         20. History of SARS-CoV-2 infection or known close contact with anyone with&#xD;
             laboratory-confirmed SARS-CoV-2 infection or COVID-19 within 2 weeks prior to vaccine&#xD;
             administration.&#xD;
&#xD;
         21. Any other condition that in the opinion of the investigator would jeopardize the&#xD;
             safety or rights of a volunteer participating in the trial or would render the subject&#xD;
             unable to comply with the protocol.&#xD;
&#xD;
             Re-Vaccination Exclusion Criteria&#xD;
&#xD;
         22. Anaphylactic reaction following administration of the investigational vaccine.&#xD;
&#xD;
         23. Virologically confirmed cases of COVID-19&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr.Vasant Khalatkar, MBBS,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meditrina Institute of Medical Sciences,Nagpur</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr.V.N Tripathi, MBBS,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prakhar Hospital Pvt Ltd.,Kanpur</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Padmavathi I V, MBBS,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Victoria Government Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr.Lokesh Kumar Tiwari, MBBS,DNB</last_name>
    <role>Principal Investigator</role>
    <affiliation>All India Institute of Medical Scienes,Patna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr.Jai Prakash Narayan, MBBS,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>JLN Medical college,Ajmer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Mirza Nizam Baig, MBBS,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pranam Hospitals Hyderabad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Prashanth Siddiah, MBBS,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cheluvambha Hospital,Mysore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. V Krishna Mohan, PhD</last_name>
    <phone>04023480567</phone>
    <email>kmohan@bharatbiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Victoria Government Hospital</name>
      <address>
        <city>Visakhapatnam</city>
        <state>Andhra Pradesh</state>
        <zip>530001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr I V Padmavathi, MBBS,MD</last_name>
      <phone>9666140568</phone>
      <email>padmavathi.vgh@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>Patna</city>
        <state>Bihar</state>
        <zip>801507</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Lokesh Tiwari, MBBS,MD</last_name>
      <phone>9555989176</phone>
      <email>lokeshkumartiwari789@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cheluvambha Hospital</name>
      <address>
        <city>Mysore</city>
        <state>Karnataka</state>
        <zip>570001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Prashanth, MBBS,MD</last_name>
      <phone>9606352062</phone>
      <email>drsp2013@rediffmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meditrina Institute of Medical Sciences</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440010</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr.Vasant Khalatkar, MBBS,MD</last_name>
      <phone>9823044438</phone>
      <email>vasant.khalatkar@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jawahar Lal Nehru Medical college</name>
      <address>
        <city>Ajmer</city>
        <state>Rajasthan</state>
        <zip>305001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Jai Prakash Narayan, MBBS,MD</last_name>
      <phone>9314294402</phone>
      <email>narayan_jaiprakash@yahoo.co.in</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pranam Hospitals Hyderabad</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500050</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Mirza Nizam Baig Baig, MBBS,MD</last_name>
      <phone>9949389002</phone>
      <email>drmnb007@yahoo.co.in</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prakhar Hospital</name>
      <address>
        <city>Kanpur</city>
        <state>Uttar Pradesh</state>
        <zip>208002</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Virendra Nath Tripathy, MBBS,MD</last_name>
      <phone>9415050777</phone>
      <email>dr.vntripathicr@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

